Vamorolone Patent Expiration
Vamorolone is Used for treating Duchenne Muscular Dystrophy. It was first introduced by Catalyst Pharmaceuticals Inc
Vamorolone Patents
Given below is the list of patents protecting Vamorolone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Agamree | US11382922 | Aqueous oral pharmaceutical suspension compositions | Jul 16, 2040 | Catalyst Pharms |
| Agamree | US11471471 | Aqueous oral pharmaceutical suspension compositions | Mar 17, 2040 | Catalyst Pharms |
| Agamree | US11690853 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | Mar 07, 2033 | Catalyst Pharms |
| Agamree | US10857161 | Non-hormonal steroid modulators of NF-kB for treatment of disease | May 28, 2029 | Catalyst Pharms |
| Agamree | US11833159 | Non-hormonal steroid modulators of NF-kB for treatment of disease | May 28, 2029 | Catalyst Pharms |
| Agamree | US8334279 | Non-hormonal steroid modulators of NF-κB for treatment of disease | May 28, 2029 | Catalyst Pharms |
Vamorolone's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List